Unlike other oncogene addictions like EGFR or ALK, KRAS G12C mutations are prevalent in smokers. This biological context means tumors are highly immunosensitive, making immunotherapy (IO) a synergistic and necessary component of treatment, rather than a conflicting one.

The focus on KRAS is expanding beyond small molecule inhibitors to diverse immunotherapies. Approaches like TCR T-cells, mRNA vaccines targeting KRAS neoepitopes, and novel amphiphil vaccines are being developed to activate a patient's immune system against their specific cancer mutations.

In frontline clinical trials for KRAS G12C NSCLC, combining olomorasib with pembrolizumab alone yielded a 90% response rate in patients with >50% PD-L1 expression. This surpassed the 78% rate seen when chemotherapy was added, suggesting a more targeted approach may be superior for this specific biomarker-defined subgroup.

In PD-L1 negative KRAS-mutated lung cancer, where standard immunotherapy is less effective, adding a CTLA-4 inhibitor can recover the immune response and create long-term survivors. This makes a triplet or quadruplet regimen the current optimal strategy for this challenging patient subgroup.

For patients with KRAS G12C non-small cell lung cancer, participation in a clinical trial offers access to next-generation inhibitors that are superior to currently approved agents. This presents a unique situation where standard of care is demonstrably behind investigational therapies.

Contrary to the standard 'TKI-first' approach for driver mutations, a study in MET exon 14 skipping NSCLC suggests a different strategy. Patients with high PD-L1 expression appeared to have better outcomes with first-line chemoimmunotherapy, reserving the targeted therapy for later. This challenges the conventional wisdom of prioritizing the driver mutation over immunotherapy biomarkers in this specific subgroup.

The combination of deveracib and pembrolizumab shows remarkably high response rates (over 70%) and a promising 19.3-month median PFS in PD-L1 positive patients. This chemotherapy-free regimen demonstrates substantial activity even in PD-L1 negative patients, suggesting a potential paradigm shift away from chemotherapy for this common mutation.

Patients progressing on first-generation KRAS G12C inhibitors may still respond to subsequent KRAS-targeted agents. Newer drugs with different binding mechanisms or greater potency are showing response rates over 40% in this post-progression setting, offering a potential new line of therapy.

Early data for next-generation KRAS G12C inhibitors combined with immunotherapy shows a doubling of both response rate (to ~75%) and progression-free survival compared to the current standard of chemo-immunotherapy. This dramatic improvement suggests these combinations will rapidly become the new standard of care.